MedKoo product information:

 Oxaliplatin

oxaliplatin is an organoplatinum complex in which the platinum atom is complexed with 1,2-diaminocyclohexane (DACH) and with an oxalate ligand as a 'leaving group.' A 'leaving group' is an atom or a group of atoms that is displaced as a stable species taking with it the bonding electrons. After displacement of the labile oxalate ligand leaving group, active oxaliplatin derivatives, such as monoaquo and diaquo DACH platinum, alkylate macromolecules, forming both inter- and intra-strand platinum-DNA crosslinks, which result in inhibition of DNA replication and transcription and cell-cycle nonspecific cytotoxicity. The DACH side chain appears to inhibit alkylating-agent resistance. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Oxaliplatin was discovered in 1976 at Nagoya City University by Professor Yoshinori Kidani, who was granted U.S. Patent 4,169,846 in 1979. Oxaliplatin was subsequently in-licensed by Debiopharm and developed as an advanced colorectal cancer treatment. Debio licensed the drug to Sanofi-Aventis in 1994. Eloxatin gained European approval in 1996 (firstly in France) and approval by the U.S. Food and Drug Administration (FDA) in 2002. The compound features a square planar platinum(II) center. In contrast to cisplatin and carboplatin, oxaliplatin features the bidentate ligand 1,2-diaminocyclohexane in place of the two monodentate ammine ligands. It also features a bidentate oxalate group. (the above information was from: http://en.wikipedia.org/wiki/Oxaliplatin).

DRUG DESCRIPTION

ELOXATIN® (oxaliplatin for injection and oxaliplatin injection) is an antineoplastic agent with the molecular formula C8H14N2O4Pt and the chemical name of cis-[(1 R,2 R)-1,2cyclohexanediamine-N,N'] [oxalato(2-)-O,O'] platinum. Oxaliplatin is an organoplatinum complex in which the platinum atom is complexed with 1,2-diaminocyclohexane(DACH) and with an oxalate ligand as a leaving group. The molecular weight is 397.3. Oxaliplatin is slightly soluble in water at 6 mg/mL, very slightly soluble in methanol, and practically insoluble in ethanol and acetone. Powder for solution for infusion: ELOXATIN is supplied in vials containing 50 mg or 100 mg of oxaliplatin as a sterile, preservative-free lyophilized powder for reconstitution. Lactose monohydrate is present as an inactive ingredient at 450 mg and 900 mg in the 50 mg and 100 mg dosage strengths, respectively. Concentrate for solution for infusion: ELOXATIN is supplied in vials containing 50 mg, 100 mg or 200 mg of oxaliplatin as a sterile, preservative-free, aqueous solution at a concentration of 5 mg/ml. Water for Injection, USP is present as an inactive ingredient.

Mechanism of Action

Oxaliplatin undergoes nonenzymatic conversion in physiologic solutions to active derivatives via displacement of the labile oxalate ligand. Several transient reactive species are formed, including monoaquo and diaquo DACH platinum, which covalently bind with macromolecules. Both inter-and intrastrand Pt-DNA crosslinks are formed. Crosslinks are formed between the N7 positions of two adjacent guanines (GG), adjacent adenine-guanines (AG), and guanines separated by an intervening nucleotide (GNG). These crosslinks inhibit DNA replication and transcription. Cytotoxicity is cell-cycle nonspecific. In vivo studies have shown antitumor activity of oxaliplatin against colon carcinoma. In combination with 5-fluorouracil , oxaliplatin exhibits in vitro and in vivo antiproliferative activity greater than either compound alone in several tumor models [HT29 (colon), GR (mammary), and L1210 (leukemia)].

  1: Tang D, Kang R, Cheh CW, Livesey KM, Liang X, Schapiro NE, Benschop R, Sparvero LJ, Amoscato AA, Tracey KJ, Zeh HJ, Lotze MT. HMGB1 release and redox regulates autophagy and apoptosis in cancer cells. Oncogene. 2010 Jul 12. [Epub ahead of print] PubMed PMID: 20622903.

2: Damia G, D'Incalci M. Genetic Instability Influences Drug Response in Cancer Cells. Curr Drug Targets. 2010 Jul 1. [Epub ahead of print] PubMed PMID: 20594166.

3: Wheate NJ, Walker S, Craig GE, Oun R. The status of platinum anticancer drugs in the clinic and in clinical trials. Dalton Trans. 2010 Jun 30. [Epub ahead of print] PubMed PMID: 20593091.

4: Zhu G, Chang P, Lippard SJ. Recognition of Platinum-DNA Damage by Poly(ADP-ribose) Polymerase-1. Biochemistry. 2010 Jun 29. [Epub ahead of print] PubMed PMID: 20550106.

5: Wang X. Fresh platinum complexes with promising antitumor activity. Anticancer Agents Med Chem. 2010 Jun 1;10(5):396-411. PubMed PMID: 20545618.

6: Muro K. [Transition of chemotherapy for metastatic colorectal cancer and recent advances]. Nippon Rinsho. 2010 Jun;68(6):1143-9. Japanese. PubMed PMID: 20535969.

7: Harper BW, Krause-Heuer AM, Grant MP, Manohar M, Garbutcheon-Singh KB, Aldrich-Wright JR. Advances in platinum chemotherapeutics. Chemistry. 2010 Jun 25;16(24):7064-77. PubMed PMID: 20533453.

8: Czejka M, Schueller J, Farkouh A, Gruenberger B, Scheithauer W. Plasma disposition of capecitabine and its metabolites 5'DFCR and 5'DFUR in a standard and dose-intensified monotherapy regimen. Cancer Chemother Pharmacol. 2010 May 22. [Epub ahead of print] PubMed PMID: 20495919.

9: Ang WH, Myint M, Lippard SJ. Transcription inhibition by platinum-DNA cross-links in live mammalian cells. J Am Chem Soc. 2010 Jun 2;132(21):7429-35. PubMed PMID: 20443565; PubMed Central PMCID: PMC2877768.

10: Zitvogel L, Kepp O, Senovilla L, Menger L, Chaput N, Kroemer G. Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway. Clin Cancer Res. 2010 Jun 15;16(12):3100-4. Epub 2010 Apr 26. PubMed PMID: 20421432.

11: Bytzek AK, Reithofer MR, Galanski M, Groessl M, Keppler BK, Hartinger CG. The first example of MEEKC-ICP-MS coupling and its application for the analysis of anticancer platinum complexes. Electrophoresis. 2010 Apr;31(7):1144-50. PubMed PMID: 20349510.

12: Hah SS, Henderson PT, Turteltaub KW. Towards biomarker-dependent individualized chemotherapy: exploring cell-specific differences in oxaliplatin-DNA adduct distribution using accelerator mass spectrometry. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2448-51. Epub 2010 Mar 7. PubMed PMID: 20335033.

13: Starha P, Trávnícek Z, Popa I. Platinum(II) oxalato complexes with adenine-based carrier ligands showing significant in vitro antitumor activity. J Inorg Biochem. 2010 Jun;104(6):639-47. Epub 2010 Mar 3. PubMed PMID: 20304500.

14: Ahmad S. Platinum-DNA interactions and subsequent cellular processes controlling sensitivity to anticancer platinum complexes. Chem Biodivers. 2010 Mar;7(3):543-66. Review. PubMed PMID: 20232326.

15: Brown SD, Nativo P, Smith JA, Stirling D, Edwards PR, Venugopal B, Flint DJ, Plumb JA, Graham D, Wheate NJ. Gold nanoparticles for the improved anticancer drug delivery of the active component of oxaliplatin. J Am Chem Soc. 2010 Apr 7;132(13):4678-84. PubMed PMID: 20225865.

16: Sonnemann J, Gressmann S, Becker S, Wittig S, Schmudde M, Beck JF. The histone deacetylase inhibitor vorinostat induces calreticulin exposure in childhood brain tumour cells in vitro. Cancer Chemother Pharmacol. 2010 Aug;66(3):611-6. Epub 2010 Mar 10. PubMed PMID: 20221600.

17: Groessl M, Tsybin YO, Hartinger CG, Keppler BK, Dyson PJ. Ruthenium versus platinum: interactions of anticancer metallodrugs with duplex oligonucleotides characterised by electrospray ionisation mass spectrometry. J Biol Inorg Chem. 2010 Jun;15(5):677-88. Epub 2010 Mar 7. PubMed PMID: 20213306.

18: Smejkal K, Svacinová J, Slapetová T, Schneiderová K, Dall'acqua S, Innocenti G, Závalová V, Kollár P, Chudík S, Marek R, Julínek O, Urbanová M, Kartal M, Csöllei M, Dolezal K. Cytotoxic activities of several geranyl-substituted flavanones. J Nat Prod. 2010 Apr 23;73(4):568-72. PubMed PMID: 20192247.

19: Olszewski U, Hamilton G. A better platinum-based anticancer drug yet to come? Anticancer Agents Med Chem. 2010 May 1;10(4):293-301. PubMed PMID: 20187870.

20: Zhang J, Wang L, Xing Z, Liu D, Sun J, Li X, Zhang Y. Status of bi- and multi-nuclear platinum anticancer drug development. Anticancer Agents Med Chem. 2010 May 1;10(4):272-82. PubMed PMID: 20184553.

21: Qu LY, Gao P, Wang HY, Wang XJ, Tang XW. [Nrf2 down-regulated cell line H460-N5 with Keap1 over-expression increased sensitivity to anti-cancer drugs]. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2010 Jan;39(1):6-10. Chinese. PubMed PMID: 20175229.

22: Lünenbürger H, Lanvers-Kaminsky C, Lechtape B, Frühwald MC. Systematic analysis of the antiproliferative effects of novel and standard anticancer agents in rhabdoid tumor cell lines. Anticancer Drugs. 2010 Jun;21(5):514-22. PubMed PMID: 20147838.

23: Aymeric L, Apetoh L, Ghiringhelli F, Tesniere A, Martins I, Kroemer G, Smyth MJ, Zitvogel L. Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity. Cancer Res. 2010 Feb 1;70(3):855-8. Epub 2010 Jan 19. Review. PubMed PMID: 20086177.

24: Bouslimani A, Bec N, Glueckmann M, Hirtz C, Larroque C. Matrix-assisted laser desorption/ionization imaging mass spectrometry of oxaliplatin derivatives in heated intraoperative chemotherapy (HIPEC)-like treated rat kidney. Rapid Commun Mass Spectrom. 2010 Feb;24(4):415-21. PubMed PMID: 20082287.

25: Burger H, Zoumaro-Djayoon A, Boersma AW, Helleman J, Berns EM, Mathijssen RH, Loos WJ, Wiemer EA. Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2). Br J Pharmacol. 2010 Feb;159(4):898-908. Epub 2010 Jan 8. PubMed PMID: 20067471; PubMed Central PMCID: PMC2829215.

26: Todd RC, Lippard SJ. Inhibition of transcription by platinum antitumor compounds. Metallomics. 2009 Jan 1;1(4):280-291. PubMed PMID: 20046924; PubMed Central PMCID: PMC2752884.

27: Ami K, Nagahama T, Ohara T, Ganno H, Hataji K, Kurokawa T, Fukuda A, Andou M, Tei S, Arai K. [A case of recurrence gastric cancer patient who was post operated and multi drug chemotherapy was effective for administration of S-1 and docetaxel combination therapy]. Gan To Kagaku Ryoho. 2009 Nov;36(12):2336-8. Japanese. PubMed PMID: 20037414.

28: Ishibashi K, Hokama N, Ishiguro T, Ohsawa T, Okada N, Miyazaki T, Yokoyama M, Inokuma S, Ishida H. [Treatment for intrapelvic recurrence of rectal cancer--resection versus chemotherapy]. Gan To Kagaku Ryoho. 2009 Nov;36(12):2226-8. Japanese. PubMed PMID: 20037378.

29: Sanchez-Cano C, Hannon MJ. Novel and emerging approaches for the delivery of metallo-drugs. Dalton Trans. 2009 Dec 28;(48):10702-11. Epub 2009 Oct 21. Review. PubMed PMID: 20023897.

30: Wang W, Sun YP, Huang XZ, He M, Chen YY, Shi GY, Li H, Yi J, Wang J. Emodin enhances sensitivity of gallbladder cancer cells to platinum drugs via glutathion depletion and MRP1 downregulation. Biochem Pharmacol. 2010 Apr 15;79(8):1134-40. Epub 2009 Dec 11. PubMed PMID: 20005210.

31: Chappuy M, Caudron E, Bellanger A, Pradeau D. Determination of platinum traces contamination by graphite furnace atomic absorption spectrometry after preconcentration by cloud point extraction. J Hazard Mater. 2010 Apr 15;176(1-3):207-12. Epub 2009 Nov 6. PubMed PMID: 19962825.

32: Kucherlapati MH, Lee K, Nguyen AA, Clark AB, Hou H Jr, Rosulek A, Li H, Yang K, Fan K, Lipkin M, Bronson RT, Jelicks L, Kunkel TA, Kucherlapati R, Edelmann W. An Msh2 conditional knockout mouse for studying intestinal cancer and testing anticancer agents. Gastroenterology. 2010 Mar;138(3):993-1002.e1. Epub 2009 Nov 18. PubMed PMID: 19931261; PubMed Central PMCID: PMC2862591.

33: Zhang J, Liu D, Li Y, Sun J, Wang L, Zang A. Status of non-classical mononuclear platinum anticancer drug development. Mini Rev Med Chem. 2009 Oct;9(11):1357-66. Review. PubMed PMID: 19929810.

34: Felth J, Rickardson L, Rosén J, Wickström M, Fryknäs M, Lindskog M, Bohlin L, Gullbo J. Cytotoxic effects of cardiac glycosides in colon cancer cells, alone and in combination with standard chemotherapeutic drugs. J Nat Prod. 2009 Nov;72(11):1969-74. PubMed PMID: 19894733.

35: Tesniere A, Schlemmer F, Boige V, Kepp O, Martins I, Ghiringhelli F, Aymeric L, Michaud M, Apetoh L, Barault L, Mendiboure J, Pignon JP, Jooste V, van Endert P, Ducreux M, Zitvogel L, Piard F, Kroemer G. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene. 2010 Jan 28;29(4):482-91. Epub 2009 Nov 2. PubMed PMID: 19881547.

36: Abu Lila AS, Doi Y, Nakamura K, Ishida T, Kiwada H. Sequential administration with oxaliplatin-containing PEG-coated cationic liposomes promotes a significant delivery of subsequent dose into murine solid tumor. J Control Release. 2010 Mar 3;142(2):167-73. Epub 2009 Oct 25. PubMed PMID: 19861140.

37: Martins I, Tesniere A, Kepp O, Michaud M, Schlemmer F, Senovilla L, Séror C, Métivier D, Perfettini JL, Zitvogel L, Kroemer G. Chemotherapy induces ATP release from tumor cells. Cell Cycle. 2009 Nov 15;8(22):3723-8. Epub 2009 Nov 8. PubMed PMID: 19855167.

38: Matsuzaki T, Yashiro M, Kaizaki R, Yasuda K, Doi Y, Sawada T, Ohira M, Hirakawa K. Synergistic antiproliferative effect of mTOR inhibitors in combination with 5-fluorouracil in scirrhous gastric cancer. Cancer Sci. 2009 Dec;100(12):2402-10. Epub 2009 Aug 18. PubMed PMID: 19764996.

39: Na HS, Lim YK, Jeong YI, Lee HS, Lim YJ, Kang MS, Cho CS, Lee HC. Combination antitumor effects of micelle-loaded anticancer drugs in a CT-26 murine colorectal carcinoma model. Int J Pharm. 2010 Jan 4;383(1-2):192-200. Epub 2009 Sep 2. PubMed PMID: 19732817.

40: Gao J, Liu YG, Zingaro RA. Cytotoxic activities, cellular uptake, gene regulation, and optical imaging of novel platinum(II) complexes. Chem Res Toxicol. 2009 Oct;22(10):1705-12. PubMed PMID: 19694485.

41: Beret EC, Provost K, Müller D, Marcos ES. Coupling CP-MD simulations and X-ray absorption spectroscopy: exploring the structure of oxaliplatin in aqueous solution. J Phys Chem B. 2009 Sep 10;113(36):12343-52. PubMed PMID: 19685899.

42: Jacobs S, McCully CL, Murphy RF, Bacher J, Balis FM, Fox E. Extracellular fluid concentrations of cisplatin, carboplatin, and oxaliplatin in brain, muscle, and blood measured using microdialysis in nonhuman primates. Cancer Chemother Pharmacol. 2010 Apr;65(5):817-24. Epub 2009 Aug 7. PubMed PMID: 19662415.

43: Zheng C, Zhou Q, Wu F, Peng Q, Tang A, Liang H, Zeng Y. Semaphorin3F down-regulates the expression of integrin alpha(v)beta3 and sensitizes multicellular tumor spheroids to chemotherapy via the neuropilin-2 receptor in vitro. Chemotherapy. 2009;55(5):344-52. Epub 2009 Aug 5. PubMed PMID: 19657188.

44: Provost K, Bouvet-Muller D, Crauste-Manciet S, Moscovici J, Olivi L, Vlaic G, Michalowicz A. EXAFS structural study of platinum-based anticancer drugs degradation in presence of sulfur nucleophilic species. Biochimie. 2009 Oct;91(10):1301-6. Epub 2009 Jul 14. PubMed PMID: 19607872.

45: Flis S, Gnyszka A, Spławiński J. HDAC inhibitors, MS275 and SBHA, enhances cytotoxicity induced by oxaliplatin in the colorectal cancer cell lines. Biochem Biophys Res Commun. 2009 Sep 18;387(2):336-41. Epub 2009 Jul 9. PubMed PMID: 19596269.

46: Preston TJ, Henderson JT, McCallum GP, Wells PG. Base excision repair of reactive oxygen species-initiated 7,8-dihydro-8-oxo-2'-deoxyguanosine inhibits the cytotoxicity of platinum anticancer drugs. Mol Cancer Ther. 2009 Jul;8(7):2015-26. Epub 2009 Jun 30. PubMed PMID: 19567822; PubMed Central PMCID: PMC2711226.

47: Vincenzi B, Santini D, Loupakis F, Addeo R, Rojas Llimpe FL, Baldi GG, Di Fabio F, Del Prete S, Pinto C, Falcone A, Tonini G. Cigarettes smoking habit may reduce benefit from cetuximab-based treatment in advanced colorectal cancer patients. Expert Opin Biol Ther. 2009 Aug;9(8):945-9. PubMed PMID: 19534585.

48: Xing R, Wang X, Zhang C, Zhang Y, Wang Q, Yang Z, Guo Z. Characterization and cellular uptake of platinum anticancer drugs encapsulated in apoferritin. J Inorg Biochem. 2009 Jul;103(7):1039-44. Epub 2009 May 13. PubMed PMID: 19501911.

49: Lissoni P, Rovelli F, Brivio F, Zago R, Colciago M, Messina G, Mora A, Porro G. A randomized study of chemotherapy versus biochemotherapy with chemotherapy plus Aloe arborescens in patients with metastatic cancer. In Vivo. 2009 Jan-Feb;23(1):171-5. PubMed PMID: 19368145.

50: Ang WH, Brown WW, Lippard SJ. Preparation of mammalian expression vectors incorporating site-specifically platinated-DNA lesions. Bioconjug Chem. 2009 May 20;20(5):1058-63. PubMed PMID: 19351185; PubMed Central PMCID: PMC2765503.

51: Hernlund E, Kutuk O, Basaga H, Linder S, Panaretakis T, Shoshan M. Cisplatin-induced nitrosylation of p53 prevents its mitochondrial translocation. Free Radic Biol Med. 2009 Jun 15;46(12):1607-13. Epub 2009 Mar 26. PubMed PMID: 19328230.

52: Oshima T, Cao X, Grande F, Yamada R, Garofalo A, Louie S, Neamati N. Combination effects of SC144 and cytotoxic anticancer agents. Anticancer Drugs. 2009 Jun;20(5):312-20. PubMed PMID: 19322070.

53: Beret EC, Pappalardo RR, Marx D, Sánchez Marcos E. Characterizing Pt-derived anticancer drugs from first principles: the case of oxaliplatin in aqueous solution. Chemphyschem. 2009 May 11;10(7):1044-52. PubMed PMID: 19253929.

54: Joseph EK, Levine JD. Comparison of oxaliplatin- and cisplatin-induced painful peripheral neuropathy in the rat. J Pain. 2009 May;10(5):534-41. Epub 2009 Feb 23. PubMed PMID: 19231296; PubMed Central PMCID: PMC2741410.

55: Plasencia C, Grande F, Oshima T, Cao X, Yamada R, Sanchez T, Aiello F, Garofalo A, Neamati N. Discovery of a novel quinoxalinhydrazide with a broad-spectrum anticancer activity. Cancer Biol Ther. 2009 Mar;8(5):458-65. Epub 2009 Mar 31. PubMed PMID: 19221468.

56: Panaretakis T, Kepp O, Brockmeier U, Tesniere A, Bjorklund AC, Chapman DC, Durchschlag M, Joza N, Pierron G, van Endert P, Yuan J, Zitvogel L, Madeo F, Williams DB, Kroemer G. Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J. 2009 Mar 4;28(5):578-90. Epub 2009 Jan 22. PubMed PMID: 19165151; PubMed Central PMCID: PMC2657583.

57: Sato S, Itamochi H, Kigawa J, Oishi T, Shimada M, Sato S, Naniwa J, Uegaki K, Nonaka M, Terakawa N. Combination chemotherapy of oxaliplatin and 5-fluorouracil may be an effective regimen for mucinous adenocarcinoma of the ovary: a potential treatment strategy. Cancer Sci. 2009 Mar;100(3):546-51. Epub 2008 Dec 19. PubMed PMID: 19154404.

58: Lucas MF, Pavelka M, Alberto ME, Russo N. Neutral and acidic hydrolysis reactions of the third generation anticancer drug oxaliplatin. J Phys Chem B. 2009 Jan 22;113(3):831-8. PubMed PMID: 19143575.

59: McWhinney SR, Goldberg RM, McLeod HL. Platinum neurotoxicity pharmacogenetics. Mol Cancer Ther. 2009 Jan;8(1):10-6. Review. PubMed PMID: 19139108; PubMed Central PMCID: PMC2651829.

60: Hellberg V, Wallin I, Eriksson S, Hernlund E, Jerremalm E, Berndtsson M, Eksborg S, Arnér ES, Shoshan M, Ehrsson H, Laurell G. Cisplatin and oxaliplatin toxicity: importance of cochlear kinetics as a determinant for ototoxicity. J Natl Cancer Inst. 2009 Jan 7;101(1):37-47. Epub 2008 Dec 30. PubMed PMID: 19116379; PubMed Central PMCID: PMC2639295.

61: Yokoyama M, Ishibashi K, Hokama N, Ishiguro T, Miyazaki T, Matsuki M, Ishida H, Gika M, Yamahata T, Eguchi K, Nakayama M, Kikuchi K. [Problems involved in the resection of pulmonary metastasis from colorectal cancer in the era of new anticancer drugs]. Gan To Kagaku Ryoho. 2008 Nov;35(12):2198-200. Japanese. PubMed PMID: 19106569.

62: Wang TT, Wei J, Qian XP, Yu LX, Liu BR. [Differential gene expression of the inhibitor of apoptosis proteins in docetaxel-resistant gastric cancer cells]. Zhonghua Zhong Liu Za Zhi. 2008 Aug;30(8):573-7. Chinese. PubMed PMID: 19102932.

63: Ford R, Schwartz L, Dancey J, Dodd LE, Eisenhauer EA, Gwyther S, Rubinstein L, Sargent D, Shankar L, Therasse P, Verweij J. Lessons learned from independent central review. Eur J Cancer. 2009 Jan;45(2):268-74. PubMed PMID: 19101138.

64: Boku N. Chemotherapy for metastatic gastric cancer in Japan. Int J Clin Oncol. 2008 Dec;13(6):483-7. Epub 2008 Dec 18. Review. PubMed PMID: 19093174.

65: Weimer LH, Sachdev N. Update on medication-induced peripheral neuropathy. Curr Neurol Neurosci Rep. 2009 Jan;9(1):69-75. Review. PubMed PMID: 19080756.

66: Lemma T, Pawliszyn J. Human serum albumin interaction with oxaliplatin studied by capillary isoelectric focusing with the whole column imaging detection and spectroscopic method. J Pharm Biomed Anal. 2009 Nov 1;50(4):570-5. Epub 2008 Nov 5. PubMed PMID: 19070448.

67: Launay-Vacher V, Isnard-Bagnis C, Janus N, Karie S, Deray G. [Chemotherapy and renal toxicity]. Bull Cancer. 2008 May 28;95 FMC Onco:F96-103. French. PubMed PMID: 18511375.

68: Altinok A, Lévi F, Goldbeter A. Identifying mechanisms of chronotolerance and chronoefficacy for the anticancer drugs 5-fluorouracil and oxaliplatin by computational modeling. Eur J Pharm Sci. 2009 Jan 31;36(1):20-38. Epub 2008 Nov 11. Review. PubMed PMID: 19041394.

69: Hu Y, Zhou T, Liao Q, Zhang TP, Chen G, Zhao YP. [Establishing the method of collagen-gel droplet embedded culture drug sensitivity test with rat tail collagen]. Zhonghua Wai Ke Za Zhi. 2008 Jul 1;46(13):998-1001. Chinese. PubMed PMID: 19035202.

70: Benhadji KA, Serova M, Ghoul A, Cvitkovic E, Le Tourneau C, Ogbourne SM, Lokiec F, Calvo F, Hammel P, Faivre S, Raymond E. Antiproliferative activity of PEP005, a novel ingenol angelate that modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cells. Br J Cancer. 2008 Dec 2;99(11):1808-15. PubMed PMID: 19034280; PubMed Central PMCID: PMC2600681.

71: Yatsuda C, Niimi M, Ono Y, Uto N, Iwagami E, Tanaka E, Yamato M. [Epiphora in a patient receiving FOLFOX therapy]. Gan To Kagaku Ryoho. 2008 Nov;35(11):1989-91. Japanese. PubMed PMID: 19011359.

72: Cheung WY, Fralick RA, Cheng S. The confused cancer patient: a case of 5-fluorouracil-induced encephalopathy. Curr Oncol. 2008 Oct;15(5):234-6. PubMed PMID: 19008998; PubMed Central PMCID: PMC2582518.

73: Pang SK, Yu CW, Guan H, Au-Yeung SC, Ho YP. Impact of oxaliplatin and a novel DACH-platinum complex in the gene expression of HCT116 colon cancer cells. Oncol Rep. 2008 Nov;20(5):1269-76. PubMed PMID: 18949432.

74: Wu B, Davey CA. Platinum drug adduct formation in the nucleosome core alters nucleosome mobility but not positioning. Chem Biol. 2008 Oct 20;15(10):1023-8. PubMed PMID: 18940663.

75: Priego S, Feddi F, Ferrer P, Mena S, Benlloch M, Ortega A, Carretero J, Obrador E, Asensi M, Estrela JM. Natural polyphenols facilitate elimination of HT-29 colorectal cancer xenografts by chemoradiotherapy: a Bcl-2- and superoxide dismutase 2-dependent mechanism. Mol Cancer Ther. 2008 Oct;7(10):3330-42. PubMed PMID: 18852136.

76: Kagiava A, Tsingotjidou A, Emmanouilides C, Theophilidis G. The effects of oxaliplatin, an anticancer drug, on potassium channels of the peripheral myelinated nerve fibres of the adult rat. Neurotoxicology. 2008 Nov;29(6):1100-6. Epub 2008 Sep 18. PubMed PMID: 18845186.

77: Wang YM, Hu LX, Liu ZM, You XF, Zhang SH, Qu JR, Li ZR, Li Y, Kong WJ, He HW, Shao RG, Zhang LR, Peng ZG, Boykin DW, Jiang JD. N-(2,6-dimethoxypyridine-3-yl)-9-methylcarbazole-3-sulfonamide as a novel tubulin ligand against human cancer. Clin Cancer Res. 2008 Oct 1;14(19):6218-27. PubMed PMID: 18829501.

78: Ozensoy Guler O, Arslan O, Kockar F. Differential in vitro inhibitory effects of anticancer drugs on tumor-associated carbonic anhydrase isozymes CA IX and CA XII. Methods Find Exp Clin Pharmacol. 2008 Jun;30(5):335-40. PubMed PMID: 18806891.

79: Ahlin G, Karlsson J, Pedersen JM, Gustavsson L, Larsson R, Matsson P, Norinder U, Bergström CA, Artursson P. Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1. J Med Chem. 2008 Oct 9;51(19):5932-42. Epub 2008 Sep 13. PubMed PMID: 18788725.

80: Kim S, Lee TJ, Park JW, Kwon TK. Overexpression of cFLIPs inhibits oxaliplatin-mediated apoptosis through enhanced XIAP stability and Akt activation in human renal cancer cells. J Cell Biochem. 2008 Nov 1;105(4):971-9. PubMed PMID: 18767116.

81: Chen Y, Ding D, Mao Z, He Y, Hu Y, Wu W, Jiang X. Synthesis of hydroxypropylcellulose-poly(acrylic acid) particles with semi-interpenetrating polymer network structure. Biomacromolecules. 2008 Oct;9(10):2609-14. Epub 2008 Aug 30. PubMed PMID: 18759474.

82: Tozawa K, Oshima T, Kobayashi T, Yamamoto N, Hayashi C, Matsumoto T, Miwa H. Oxaliplatin in treatment of the cisplatin-resistant MKN45 cell line of gastric cancer. Anticancer Res. 2008 Jul-Aug;28(4B):2087-92. PubMed PMID: 18751380.

83: Alberto ME, Lucas MF, Pavelka M, Russo N. The degradation pathways in chloride medium of the third generation anticancer drug oxaliplatin. J Phys Chem B. 2008 Sep 4;112(35):10765-8. Epub 2008 Aug 12. PubMed PMID: 18698718.

84: Wheate NJ. Improving platinum(II)-based anticancer drug delivery using cucurbit[n]urils. J Inorg Biochem. 2008 Dec;102(12):2060-6. Epub 2008 Jun 20. Review. PubMed PMID: 18653238.

85: Treiber G, Wex T, Malfertheiner P. Impact of different anticancer regimens on biomarkers of angiogenesis in patients with advanced hepatocellular cancer. J Cancer Res Clin Oncol. 2009 Feb;135(2):271-81. Epub 2008 Jul 19. PubMed PMID: 18642029.

86: He Z, Gao J, Wang Q, Liu M, Li Y, Li X, Tang H, Zheng J. S100P contributes to chemosensitivity of human ovarian cancer cell line OVCAR3. Oncol Rep. 2008 Aug;20(2):325-32. PubMed PMID: 18636193.

87: Pozzo C, Barone C. Is there an optimal chemotherapy regimen for the treatment of advanced gastric cancer that will provide a platform for the introduction of new biological agents? Oncologist. 2008 Jul;13(7):794-806. Epub 2008 Jul 9. PubMed PMID: 18614586.

88: Lovejoy KS, Todd RC, Zhang S, McCormick MS, D'Aquino JA, Reardon JT, Sancar A, Giacomini KM, Lippard SJ. cis-Diammine(pyridine)chloroplatinum(II), a monofunctional platinum(II) antitumor agent: Uptake, structure, function, and prospects. Proc Natl Acad Sci U S A. 2008 Jul 1;105(26):8902-7. Epub 2008 Jun 25. PubMed PMID: 18579768; PubMed Central PMCID: PMC2449337.

89: Vincenzi B, Schiavon G, Pantano F, Santini D, Tonini G. Predictive factors for chemotherapy-related toxic effects in patients with colorectal cancer. Nat Clin Pract Oncol. 2008 Aug;5(8):455-65. Epub 2008 Jun 10. Review. PubMed PMID: 18542119.

90: Correale P, Del Vecchio MT, La Placa M, Montagnani F, Di Genova G, Savellini GG, Terrosi C, Mannucci S, Giorgi G, Francini G, Cusi MG. Chemotherapeutic drugs may be used to enhance the killing efficacy of human tumor antigen peptide-specific CTLs. J Immunother. 2008 Feb-Mar;31(2):132-47. PubMed PMID: 18481383.

91: Correale P, Fioravanti A, Bertoldi I, Montagnani F, Miracco C, Francini G. Occurrence of autoimmunity in a long-term survivor with metastatic colon carcinoma treated with a new chemo-immunotherapy regimen. J Chemother. 2008 Apr;20(2):278-81. PubMed PMID: 18467257.

92: Dean-Colomb W, Esteva FJ. Emerging agents in the treatment of anthracycline- and taxane-refractory metastatic breast cancer. Semin Oncol. 2008 Apr;35(2 Suppl 2):S31-8; quiz S40. Review. PubMed PMID: 18410797.

93: Lemma T, Mandal R, Li XF, Pawliszyn J. Investigation of interaction between human hemoglobin A0 and platinum anticancer drugs by capillary isoelectric focusing with whole column imaging detection. J Sep Sci. 2008 Jun;31(10):1803-9. PubMed PMID: 18446809.

94: Istomin YP, Zhavrid EA, Alexandrova EN, Sergeyeva OP, Petrovich SV. Dose enhancement effect of anticaner drugs associated with increased temperature in vitro. Exp Oncol. 2008 Mar;30(1):56-9. PubMed PMID: 18438342.

95: Heffeter P, Jungwirth U, Jakupec M, Hartinger C, Galanski M, Elbling L, Micksche M, Keppler B, Berger W. Resistance against novel anticancer metal compounds: differences and similarities. Drug Resist Updat. 2008 Feb-Apr;11(1-2):1-16. Epub 2008 Apr 3. Review. PubMed PMID: 18394950.

96: Baker AF, Koh MY, Williams RR, James B, Wang H, Tate WR, Gallegos A, Von Hoff DD, Han H, Powis G. Identification of thioredoxin-interacting protein 1 as a hypoxia-inducible factor 1alpha-induced gene in pancreatic cancer. Pancreas. 2008 Mar;36(2):178-86. PubMed PMID: 18376310.

97: Benzina S, Altmeyer A, Malek F, Dufour P, Denis JM, Gueulette J, Bischoff P. High-LET radiation combined with oxaliplatin induce autophagy in U-87 glioblastoma cells. Cancer Lett. 2008 Jun 8;264(1):63-70. Epub 2008 Mar 10. PubMed PMID: 18329790.

98: Galanski M. Recent developments in the field of anticancer platinum complexes. Recent Pat Anticancer Drug Discov. 2006 Jun;1(2):285-95. Review. PubMed PMID: 18221042.

99: Sereno M, Brunello A, Chiappori A, Barriuso J, Casado E, Belda C, de Castro J, Feliu J, González-Barón M. Cardiac toxicity: old and new issues in anti-cancer drugs. Clin Transl Oncol. 2008 Jan;10(1):35-46. Review. PubMed PMID: 18208791.

100: Wu B, Dröge P, Davey CA. Site selectivity of platinum anticancer therapeutics. Nat Chem Biol. 2008 Feb;4(2):110-2. Epub 2007 Dec 23. PubMed PMID: 18157123.

101: Lissoni P, Fumagalli L, Brivio F, Rovelli F, Messina G, Di Fede G, Colciago M, Brera G. Cancer chemotherapy-induced lymphocytosis: a revolutionary discovery in the medical oncology. J Biol Regul Homeost Agents. 2006 Jan-Jun;20(1-2):29-35. PubMed PMID: 18088552.

102: Hartinger CG, Tsybin YO, Fuchser J, Dyson PJ. Characterization of platinum anticancer drug protein-binding sites using a top-down mass spectrometric approach. Inorg Chem. 2008 Jan 7;47(1):17-9. Epub 2007 Dec 8. PubMed PMID: 18067289.

103: Lévi F. The circadian timing system, a coordinator of life processes. implications for the rhythmic delivery of cancer therapeutics. Conf Proc IEEE Eng Med Biol Soc. 2006;Suppl:6736-9. Review. PubMed PMID: 17959499.

104: Kasparkova J, Vojtiskova M, Natile G, Brabec V. Unique properties of DNA interstrand cross-links of antitumor oxaliplatin and the effect of chirality of the carrier ligand. Chemistry. 2008;14(4):1330-41. PubMed PMID: 18022972.

105: Kannarkat G, Lasher EE, Schiff D. Neurologic complications of chemotherapy agents. Curr Opin Neurol. 2007 Dec;20(6):719-25. Review. PubMed PMID: 17992096.

106: Jiang X, Galettis P, Links M, Mitchell PL, McLachlan AJ. Population pharmacokinetics of gemcitabine and its metabolite in patients with cancer: effect of oxaliplatin and infusion rate. Br J Clin Pharmacol. 2008 Mar;65(3):326-33. Epub 2007 Oct 24. PubMed PMID: 17961191; PubMed Central PMCID: PMC2291243.

107: Yu Y, Lou LG, Liu WP, Zhu HJ, Ye QS, Chen XZ, Gao WG, Hou SQ. Synthesis and anticancer activity of lipophilic platinum(II) complexes of 3,5-diisopropylsalicylate. Eur J Med Chem. 2008 Jul;43(7):1438-43. Epub 2007 Sep 19. PubMed PMID: 17959272.

108: Song TY, Lin HC, Yang NC, Hu ML. Antiproliferative and antimetastatic effects of the ethanolic extract of Phellinus igniarius (Linnearus: Fries) Quelet. J Ethnopharmacol. 2008 Jan 4;115(1):50-6. Epub 2007 Sep 8. PubMed PMID: 17936529.

109: Sharma S, Gong P, Temple B, Bhattacharyya D, Dokholyan NV, Chaney SG. Molecular dynamic simulations of cisplatin- and oxaliplatin-d(GG) intrastand cross-links reveal differences in their conformational dynamics. J Mol Biol. 2007 Nov 9;373(5):1123-40. Epub 2007 Aug 23. PubMed PMID: 17900616; PubMed Central PMCID: PMC2129172.

110: Pang SK, Yu CW, Au-Yeung SC, Ho YP. DNA damage induced by novel demethylcantharidin-integrated platinum anticancer complexes. Biochem Biophys Res Commun. 2007 Nov 9;363(1):235-40. Epub 2007 Sep 7. PubMed PMID: 17868646.

111: Jung GR, Kim KJ, Choi CH, Lee TB, Han SI, Han HK, Lim SC. Effect of betulinic acid on anticancer drug-resistant colon cancer cells. Basic Clin Pharmacol Toxicol. 2007 Oct;101(4):277-85. PubMed PMID: 17845510.

112: Vormittag L, Kornek GV, Gruhsmann B, Lenauer A, Föger A, Depisch D, Lang F, Scheithauer W. UFT/leucovorin and mitomycin C as salvage treatment in patients with advanced colorectal cancer - a retrospective analysis. Anticancer Drugs. 2007 Jul;18(6):709-12. PubMed PMID: 17762401.

113: Tang H, Liu YJ, Liu M, Li X. Establishment and gene analysis of an oxaliplatin-resistant colon cancer cell line THC8307/L-OHP. Anticancer Drugs. 2007 Jul;18(6):633-9. PubMed PMID: 17762391.

114: Lévi F, Focan C, Karaboué A, de la Valette V, Focan-Henrard D, Baron B, Kreutz F, Giacchetti S. Implications of circadian clocks for the rhythmic delivery of cancer therapeutics. Adv Drug Deliv Rev. 2007 Aug 31;59(9-10):1015-35. Epub 2007 Jul 4. Review. PubMed PMID: 17692427.

115: Serova M, Galmarini CM, Ghoul A, Benhadji K, Green SR, Chiao J, Faivre S, Cvitkovic E, Le Tourneau C, Calvo F, Raymond E. Antiproliferative effects of sapacitabine (CYC682), a novel 2'-deoxycytidine-derivative, in human cancer cells. Br J Cancer. 2007 Sep 3;97(5):628-36. Epub 2007 Jul 17. PubMed PMID: 17637678; PubMed Central PMCID: PMC2360357.

116: Seymour MT, Maughan TS, Ledermann JA, Topham C, James R, Gwyther SJ, Smith DB, Shepherd S, Maraveyas A, Ferry DR, Meade AM, Thompson L, Griffiths GO, Parmar MK, Stephens RJ; FOCUS Trial Investigators; National Cancer Research Institute Colorectal Clinical Studies Group. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet. 2007 Jul 14;370(9582):143-52. Erratum in: Lancet. 2007 Aug 18;370(9587):566. PubMed PMID: 17630037.

117: Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 2007 Aug;7(8):573-84. Epub 2007 Jul 12. Review. PubMed PMID: 17625587.

118: Ceppa F, Fontan E, Cremades S, Bihannic R, Bousquet A, Beauvillain L, Burnat P. [Role of pharmacogenetics in chemotherapy of colorectal cancers]. Rev Med Interne. 2007 Sep;28(9):594-602. Epub 2007 Apr 18. French. PubMed PMID: 17624636.

119: Overman MJ, Hoff PM. EGFR-targeted therapies in colorectal cancer. Dis Colon Rectum. 2007 Aug;50(8):1259-70. Review. PubMed PMID: 17566832.

120: Wu Y, Bhattacharyya D, King CL, Baskerville-Abraham I, Huh SH, Boysen G, Swenberg JA, Temple B, Campbell SL, Chaney SG. Solution structures of a DNA dodecamer duplex with and without a cisplatin 1,2-d(GG) intrastrand cross-link: comparison with the same DNA duplex containing an oxaliplatin 1,2-d(GG) intrastrand cross-link. Biochemistry. 2007 Jun 5;46(22):6477-87. Epub 2007 May 12. PubMed PMID: 17497831; PubMed Central PMCID: PMC2129171.

121: Lissoni P. Biochemotherapy with standard chemotherapies plus the pineal hormone melatonin in the treatment of advanced solid neoplasms. Pathol Biol (Paris). 2007 Apr-May;55(3-4):201-4. Epub 2007 Apr 18. PubMed PMID: 17446010.

122: Tao Z, Goodisman J, Penefsky HS, Souid AK. Caspase activation by anticancer drugs: the caspase storm. Mol Pharm. 2007 Jul-Aug;4(4):583-95. Epub 2007 Apr 17. PubMed PMID: 17439154.

123: Benzina S, Debomy F, Bergerat JP, Denis JM, Gueulette J, Dufour P, Bischoff P. The cytotoxicity of high-linear energy transfer radiation is reinforced by oxaliplatin in human glioblastoma cells. Cancer Lett. 2007 Aug 28;254(1):54-62. Epub 2007 Mar 26. PubMed PMID: 17383816.

124: Saif MW, Kang SP, Chu E. Treatment of metastatic colorectal cancer: from cytotoxic agents to molecular agents and multitargeted strategies. Oncology (Williston Park). 2006 Dec;20(14 Suppl 10):11-9. Review. PubMed PMID: 17354513.

125: Neri B, Pantaleo P, Giommoni E, Grifoni R, Paoletti C, Rotella V, Pantalone D, Taddei A, Mercatelli A, Tonelli P. Oxaliplatin, 5-fluorouracil/leucovorin and epirubicin as first-line treatment in advanced gastric carcinoma: a phase II study. Br J Cancer. 2007 Apr 10;96(7):1043-6. Epub 2007 Mar 13. PubMed PMID: 17353926; PubMed Central PMCID: PMC2360129.

126: Takagi A, Watanabe M, Ishii Y, Morita J, Hirokawa Y, Matsuzaki T, Shiraishi T. Three-dimensional cellular spheroid formation provides human prostate tumor cells with tissue-like features. Anticancer Res. 2007 Jan-Feb;27(1A):45-53. PubMed PMID: 17352215.

127: Berger I, Nazarov AA, Hartinger CG, Groessl M, Valiahdi SM, Jakupec MA, Keppler BK. A glucose derivative as natural alternative to the cyclohexane-1,2-diamine ligand in the anticancer drug oxaliplatin? ChemMedChem. 2007 Apr;2(4):505-14. PubMed PMID: 17340670.

128: Li YF, Fu S, Hu W, Liu JH, Finkel KW, Gershenson DM, Kavanagh JJ. Systemic anticancer therapy in gynecological cancer patients with renal dysfunction. Int J Gynecol Cancer. 2007 Jul-Aug;17(4):739-63. Epub 2007 Feb 16. Review. PubMed PMID: 17309673.

129: Mori K. [Introduction "why is it multinational clinical trial now?"]. Gan To Kagaku Ryoho. 2007 Feb;34(2):290-2. Japanese. PubMed PMID: 17301546.

130: Galanski M, Keppler BK. Searching for the magic bullet: anticancer platinum drugs which can be accumulated or activated in the tumor tissue. Anticancer Agents Med Chem. 2007 Jan;7(1):55-73. Review. PubMed PMID: 17266505.

131: Cepeda V, Fuertes MA, Castilla J, Alonso C, Quevedo C, Pérez JM. Biochemical mechanisms of cisplatin cytotoxicity. Anticancer Agents Med Chem. 2007 Jan;7(1):3-18. Review. PubMed PMID: 17266502.

132: Temmink OH, Hoebe EK, van der Born K, Ackland SP, Fukushima M, Peters GJ. Mechanism of trifluorothymidine potentiation of oxaliplatin-induced cytotoxicity to colorectal cancer cells. Br J Cancer. 2007 Jan 29;96(2):231-40. PubMed PMID: 17242697; PubMed Central PMCID: PMC2360012.

133: Benoit E, Brienza S, Dubois JM. Oxaliplatin, an anticancer agent that affects both Na+ and K+ channels in frog peripheral myelinated axons. Gen Physiol Biophys. 2006 Sep;25(3):263-76. PubMed PMID: 17197725.

134: Casini A, Mastrobuoni G, Temperini C, Gabbiani C, Francese S, Moneti G, Supuran CT, Scozzafava A, Messori L. ESI mass spectrometry and X-ray diffraction studies of adducts between anticancer platinum drugs and hen egg white lysozyme. Chem Commun (Camb). 2007 Jan 14;(2):156-8. Epub 2006 Oct 26. PubMed PMID: 17180231.

135: Lenz HJ. Pharmacogenomics and colorectal cancer. Adv Exp Med Biol. 2006;587:211-31. Review. PubMed PMID: 17163168.

136: Pasetto LM, Bortolami A, Falci C, Sinigaglia G, Monfardini S. Recent progress in target therapy in colorectal cancer. Anticancer Res. 2006 Sep-Oct;26(5B):3973-81. Review. PubMed PMID: 17094429.

137: Bouvet D, Michalowicz A, Crauste-Manciet S, Curis E, Nicolis I, Olivi L, Vlaic G, Brossard D, Provost K. EXAFS characterization of oxaliplatin anticancer drug and its degradation in chloride media. J Synchrotron Radiat. 2006 Nov;13(Pt 6):477-83. Epub 2006 Oct 18. PubMed PMID: 17057326.

138: Chiu SJ, Hsu TS, Chao JI. Opposing securin and p53 protein expression in the oxaliplatin-induced cytotoxicity of human colorectal cancer cells. Toxicol Lett. 2006 Dec 1;167(2):122-30. Epub 2006 Sep 15. PubMed PMID: 17045763.

139: Zhang S, Lovejoy KS, Shima JE, Lagpacan LL, Shu Y, Lapuk A, Chen Y, Komori T, Gray JW, Chen X, Lippard SJ, Giacomini KM. Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 2006 Sep 1;66(17):8847-57. PubMed PMID: 16951202; PubMed Central PMCID: PMC2775093.

140: Brouwers EE, Tibben MM, Rosing H, Hillebrand MJ, Joerger M, Schellens JH, Beijnen JH. Sensitive inductively coupled plasma mass spectrometry assay for the determination of platinum originating from cisplatin, carboplatin, and oxaliplatin in human plasma ultrafiltrate. J Mass Spectrom. 2006 Sep;41(9):1186-94. PubMed PMID: 16929560.

141: Yonezawa A, Masuda S, Yokoo S, Katsura T, Inui K. Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther. 2006 Nov;319(2):879-86. Epub 2006 Aug 16. PubMed PMID: 16914559.

142: Mandal R, Sawyer MB, Li XF. Mass spectrometry study of hemoglobin-oxaliplatin complexes in colorectal cancer patients and potential association with chemotherapeutic responses. Rapid Commun Mass Spectrom. 2006;20(17):2533-8. PubMed PMID: 16878345.

143: Giacchetti S, Bjarnason G, Garufi C, Genet D, Iacobelli S, Tampellini M, Smaaland R, Focan C, Coudert B, Humblet Y, Canon JL, Adenis A, Lo Re G, Carvalho C, Schueller J, Anciaux N, Lentz MA, Baron B, Gorlia T, Lévi F; European Organisation for Research and Treatment of Cancer Chronotherapy Group. Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group. J Clin Oncol. 2006 Aug 1;24(22):3562-9. PubMed PMID: 16877722.

144: Zhang X, Yashiro M, Ren J, Hirakawa K. Histone deacetylase inhibitor, trichostatin A, increases the chemosensitivity of anticancer drugs in gastric cancer cell lines. Oncol Rep. 2006 Sep;16(3):563-8. PubMed PMID: 16865256.

145: Hastie CJ, Vázquez-Martin C, Philp A, Stark MJ, Cohen PT. The Saccharomyces cerevisiae orthologue of the human protein phosphatase 4 core regulatory subunit R2 confers resistance to the anticancer drug cisplatin. FEBS J. 2006 Jul;273(14):3322-34. PubMed PMID: 16857015.

146: Cerè V, Grossi L, Munari D, Pollicino S, Martelli L, Martelli M. Platinum (II) complexes with stereochemically-defined thiepane dioxide diamine ligands as anticancer drugs. Anticancer Res. 2006 May-Jun;26(3A):1815-9. PubMed PMID: 16827112.

147: Arnold D, Peinert S, Voigt W, Schmoll HJ. Epidermal growth factor receptor tyrosine kinase inhibitors: present and future role in gastrointestinal cancer treatment: a review. Oncologist. 2006 Jun;11(6):602-11. Review. PubMed PMID: 16794239.

148: Helleman J, Burger H, Hamelers IH, Boersma AW, de Kroon AI, Stoter G, Nooter K. Impaired cisplatin influx in an A2780 mutant cell line: evidence for a putative, cis-configuration-specific, platinum influx transporter. Cancer Biol Ther. 2006 Aug;5(8):943-9. Epub 2006 Aug 2. PubMed PMID: 16775422.

149: Cerea G, Ricotta R, Schiavetto I, Maugeri MR, Sartore-Bianchi A, Moroni M, Artale S, Siena S. Cetuximab for treatment of metastatic colorectal cancer. Ann Oncol. 2006 Jun;17 Suppl 7:vii66-7. PubMed PMID: 16760297.

150: Borner MM. [Molecular targets in colon cancer]. Ther Umsch. 2006 Apr;63(4):243-8. Review. German. PubMed PMID: 16689454.

151: Ludwig T, Fakih S, Bertram H, Krebs B, Oberleithner H. New imidazole-coordinated chemotherapeutics with low epithelial toxicity. Cell Biochem Biophys. 2006;45(1):31-41. PubMed PMID: 16679562.

152: Ardavanis AS, Ioannidis GN, Orphanos GS, Rigatos GA. Salvage treatment with single-agent capecitabine in patients with heavily pretreated advanced colorectal cancer. Anticancer Res. 2006 Mar-Apr;26(2B):1669-72. PubMed PMID: 16619589.

153: Bouvet D, Michalowicz A, Crauste-Manciet S, Brossard D, Provost K. EXAFS and IR structural study of platinum-based anticancer drugs' degradation by diethyl dithiocarbamate. Inorg Chem. 2006 Apr 17;45(8):3393-8. PubMed PMID: 16602799.

154: Lévi F. Chronotherapeutics: the relevance of timing in cancer therapy. Cancer Causes Control. 2006 May;17(4):611-21. Review. PubMed PMID: 16596317.

155: Piacentini P, Donadelli M, Costanzo C, Moore PS, Palmieri M, Scarpa A. Trichostatin A enhances the response of chemotherapeutic agents in inhibiting pancreatic cancer cell proliferation. Virchows Arch. 2006 Jun;448(6):797-804. Epub 2006 Mar 28. PubMed PMID: 16568310.

156: Mijatovic T, Op De Beeck A, Van Quaquebeke E, Dewelle J, Darro F, de Launoit Y, Kiss R. The cardenolide UNBS1450 is able to deactivate nuclear factor kappaB-mediated cytoprotective effects in human non-small cell lung cancer cells. Mol Cancer Ther. 2006 Feb;5(2):391-9. PubMed PMID: 16505114.

157: Mizutani Y, Nakamura T, Nomoto T, Kawauchi A, Miki T. [Progress in therapy for testicular tumors]. Gan To Kagaku Ryoho. 2006 Feb;33(2):183-7. Review. Japanese. PubMed PMID: 16484853.

158: Alexandre J, Nicco C, Chéreau C, Laurent A, Weill B, Goldwasser F, Batteux F. Improvement of the therapeutic index of anticancer drugs by the superoxide dismutase mimic mangafodipir. J Natl Cancer Inst. 2006 Feb 15;98(4):236-44. PubMed PMID: 16478742.

159: Yu CW, Li KK, Pang SK, Au-Yeung SC, Ho YP. Anticancer activity of a series of platinum complexes integrating demethylcantharidin with isomers of 1,2-diaminocyclohexane. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1686-91. Epub 2006 Jan 4. PubMed PMID: 16386904.

160: Machiels JP, Duck L, Honhon B, Coster B, Coche JC, Scalliet P, Humblet Y, Aydin S, Kerger J, Remouchamps V, Canon JL, Van Maele P, Gilbeau L, Laurent S, Kirkove C, Octave-Prignot M, Baurain JF, Kartheuser A, Sempoux C. Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with rectal cancer: the RadiOxCape study. Ann Oncol. 2005 Dec;16(12):1898-905. Epub 2005 Oct 11. PubMed PMID: 16219623.

161: Umapathi T, Chaudhry V. Toxic neuropathy. Curr Opin Neurol. 2005 Oct;18(5):574-80. Review. PubMed PMID: 16155443.

162: Eklund JW, Trifilio S, Mulcahy MF. Chemotherapy dosing in the setting of liver dysfunction. Oncology (Williston Park). 2005 Jul;19(8):1057-63; discussion 1063-4, 1069. Review. PubMed PMID: 16131047.

163: Galanski M, Jakupec MA, Keppler BK. Update of the preclinical situation of anticancer platinum complexes: novel design strategies and innovative analytical approaches. Curr Med Chem. 2005;12(18):2075-94. Review. PubMed PMID: 16101495.

164: Bellone G, Novarino A, Chiappino I, Gramigni C, Carbone A, Addeo A, Tonel E, Bertetto O, Emanuelli G. Circulating vascular endothelial growth factor and interferon-gamma-inducible protein-10 levels in pancreatic cancer during chemotherapy. Anticancer Res. 2005 Sep-Oct;25(5):3287-91. PubMed PMID: 16101140.

165: Witte AB, Anestål K, Jerremalm E, Ehrsson H, Arnér ES. Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds. Free Radic Biol Med. 2005 Sep 1;39(5):696-703. PubMed PMID: 16085187.

166: Correale P, Cusi MG, Tsang KY, Del Vecchio MT, Marsili S, Placa ML, Intrivici C, Aquino A, Micheli L, Nencini C, Ferrari F, Giorgi G, Bonmassar E, Francini G. Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients. J Clin Oncol. 2005 Dec 10;23(35):8950-8. Epub 2005 Aug 1. PubMed PMID: 16061910.

167: McKeage MJ. New-generation platinum drugs in the treatment of cisplatin-resistant cancers. Expert Opin Investig Drugs. 2005 Aug;14(8):1033-46. Review. PubMed PMID: 16050795.

168: Habala L, Galanski M, Yasemi A, Nazarov AA, von Keyserlingk NG, Keppler BK. Synthesis and structure-activity relationships of mono- and dialkyl-substituted oxaliplatin derivatives. Eur J Med Chem. 2005 Nov;40(11):1149-55. Epub 2005 Jul 22. PubMed PMID: 16040163.

169: Coudray AM, Louvet C, Kornprobst M, Raymond E, André T, Tournigand C, Faivre S, De Gramont A, Larsen AK, Gespach C. Increased anticancer activity of the thymidylate synthase inhibitor BGC9331 combined with the topoisomerase I inhibitor SN-38 in human colorectal and breast cancer cells: induction of apoptosis and ROCK cleavage through caspase-3-dependent and -independent mechanisms. Int J Oncol. 2005 Aug;27(2):553-61. PubMed PMID: 16010439.

170: Lin J, Hsiao PW, Chiu TH, Chao JI. Combination of cyclooxygenase-2 inhibitors and oxaliplatin increases the growth inhibition and death in human colon cancer cells. Biochem Pharmacol. 2005 Sep 1;70(5):658-67. PubMed PMID: 16004971.

171: Oki Y, McLaughlin P, Pro B, Hagemeister FB, Bleyer A, Loyer E, Younes A. Phase II study of oxaliplatin in patients with recurrent or refractory non-Hodgkin lymphoma. Cancer. 2005 Aug 15;104(4):781-7. PubMed PMID: 15973667.

172: Zhao YY, Mandal R, Li XF. Intact human holo-transferrin interaction with oxaliplatin. Rapid Commun Mass Spectrom. 2005;19(14):1956-62. PubMed PMID: 15954173.

173: Aggarwal S, Chu E. Current therapies for advanced colorectal cancer. Oncology (Williston Park). 2005 Apr;19(5):589-95. Review. PubMed PMID: 15945340.

174: Levêque D, Michallat AC, Schaller C, Ranc M. [Off label drug use in adult patients treated by anticancer chemotherapy]. Bull Cancer. 2005 May 1;92(5):498-500. French. PubMed PMID: 15932813.

175: Dell'Erba C, Chiavarina B, Fenoglio C, Petrillo G, Cordazzo C, Boncompagni E, Spinelli D, Ognio E, Aiello C, Mariggiò MA, Viale M. Inhibition of cell proliferation, cytotoxicity and induction of apoptosis of 1,4-bis(1-naphthyl)-2,3-dinitro-1,3-butadiene in gastrointestinal tumour cell lines and preliminary evaluation of its toxicity in vivo. Pharmacol Res. 2005 Sep;52(3):271-82. PubMed PMID: 15921920.

176: Cohen PT, Philp A, Vázquez-Martin C. Protein phosphatase 4--from obscurity to vital functions. FEBS Lett. 2005 Jun 13;579(15):3278-86. Review. PubMed PMID: 15913612.

177: Pestalozzi BC, Jäger D, Knuth A. [Systemic therapy for colorectal cancer]. Chirurg. 2005 Jun;76(6):570-2, 574. German. PubMed PMID: 15905968.

178: Robert J, Morvan VL, Smith D, Pourquier P, Bonnet J. Predicting drug response and toxicity based on gene polymorphisms. Crit Rev Oncol Hematol. 2005 Jun;54(3):171-96. Review. PubMed PMID: 15890268.

179: Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov. 2005 Apr;4(4):307-20. Review. PubMed PMID: 15789122.

180: Rudnev AV, Aleksenko SS, Semenova O, Hartinger CG, Timerbaev AR, Keppler BK. Determination of binding constants and stoichiometries for platinum anticancer drugs and serum transport proteins by capillary electrophoresis using the Hummel-Dreyer method. J Sep Sci. 2005 Feb;28(2):121-7. PubMed PMID: 15754818.

181: Belani CP. Recent updates in the clinical use of platinum compounds for the treatment of lung, breast, and genitourinary tumors and myeloma. Semin Oncol. 2004 Dec;31(6 Suppl 14):25-33. Review. PubMed PMID: 15726531.

182: Rappel C, Galanski M, Yasemi A, Habala L, Keppler BK. Analysis of anticancer platinum(II)-complexes by microemulsion electrokinetic chromatography: separation of diastereomers and estimation of octanol-water partition coefficients. Electrophoresis. 2005 Feb;26(4-5):878-84. PubMed PMID: 15714548.

183: Peters GJ, Smorenburg CH, Van Groeningen CJ. Prospective clinical trials using a pharmacogenetic/pharmacogenomic approach. J Chemother. 2004 Nov;16 Suppl 4:25-30. Review. PubMed PMID: 15688605.

184: Hanauske AR, Dittrich C, Otero J. Overview of phase I/II pemetrexed studies. Oncology (Williston Park). 2004 Nov;18(13 Suppl 8):18-25. Review. PubMed PMID: 15655932.

185: Espinosa M, Martinez M, Aguilar JL, Mota A, De la Garza JG, Maldonado V, Meléndez-Zajgla J. Oxaliplatin activity in head and neck cancer cell lines. Cancer Chemother Pharmacol. 2005 Mar;55(3):301-5. Epub 2004 Oct 21. PubMed PMID: 15619139.

186: Fojo T, Farrell N, Ortuzar W, Tanimura H, Weinstein J, Myers TG. Identification of non-cross-resistant platinum compounds with novel cytotoxicity profiles using the NCI anticancer drug screen and clustered image map visualizations. Crit Rev Oncol Hematol. 2005 Jan;53(1):25-34. PubMed PMID: 15607933.

187: Safaei R, Howell SB. Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. Crit Rev Oncol Hematol. 2005 Jan;53(1):13-23. Review. PubMed PMID: 15607932.

188: Wolf W, Presant CA. Tumor-based pharmacokinetics has greater significance for anticancer drugs than does blood-based pharmacokinetics. Clin Pharmacol Ther. 2004 Nov;76(5):508; author reply 508-9. PubMed PMID: 15536466.

189: Sarmiento R, Saponiero A, Gasparini G. Therapeutic strategies to improve the efficacy of oxaliplatin in gastrointestinal tumors. Int J Biol Markers. 2004 Jul-Sep;19(3):183-9. Review. PubMed PMID: 15503819.

190: Medinger M, Steinbild S, Mross K. [Adjuvant and palliative anticancer treatment of colon carcinoma in 2004]. Praxis (Bern 1994). 2004 Sep 29;93(40):1633-44. Review. German. PubMed PMID: 15495753.

191: Dagher R, Johnson J, Williams G, Keegan P, Pazdur R. Accelerated approval of oncology products: a decade of experience. J Natl Cancer Inst. 2004 Oct 20;96(20):1500-9. Review. PubMed PMID: 15494600.

192: Pestalozzi BC, Jäger D, Knuth A. [New drugs for colorectal cancer]. Praxis (Bern 1994). 2004 Sep 1;93(36):1455-9. German. PubMed PMID: 15487860.

193: Chaney SG, Campbell SL, Temple B, Bassett E, Wu Y, Faldu M. Protein interactions with platinum-DNA adducts: from structure to function. J Inorg Biochem. 2004 Oct;98(10):1551-9. PubMed PMID: 15458816.

194: Sternberg CN, Reichardt P, Holland M. Development of and clinical experience with capecitabine (Xeloda) in the treatment of solid tumours. Eur J Oncol Nurs. 2004;8 Suppl 1:S4-15. Review. PubMed PMID: 15341878.

195: Galanski M, Yasemi A, Slaby S, Jakupec MA, Arion VB, Rausch M, Nazarov AA, Keppler BK. Synthesis, crystal structure and cytotoxicity of new oxaliplatin analogues indicating that improvement of anticancer activity is still possible. Eur J Med Chem. 2004 Aug;39(8):707-14. PubMed PMID: 15276304.

196: Youn CK, Kim MH, Cho HJ, Kim HB, Chang IY, Chung MH, You HJ. Oncogenic H-Ras up-regulates expression of ERCC1 to protect cells from platinum-based anticancer agents. Cancer Res. 2004 Jul 15;64(14):4849-57. Erratum in: Cancer Res. 2004 Nov 15;64(22):8484. PubMed PMID: 15256455.

197: Gamelin L, Boisdron-Celle M, Delva R, Guérin-Meyer V, Ifrah N, Morel A, Gamelin E. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4055-61. PubMed PMID: 15217938.

198: Barnes KR, Lippard SJ. Cisplatin and related anticancer drugs: recent advances and insights. Met Ions Biol Syst. 2004;42:143-77. Review. PubMed PMID: 15206102.

199: Wu HI, Brown JA, Dorie MJ, Lazzeroni L, Brown JM. Genome-wide identification of genes conferring resistance to the anticancer agents cisplatin, oxaliplatin, and mitomycin C. Cancer Res. 2004 Jun 1;64(11):3940-8. PubMed PMID: 15173006.

200: Chen JY, Liang DM, Gan P, Zhang Y, Lin J. In vitro effects of recombinant human growth hormone on growth of human gastric cancer cell line BGC823 cells. World J Gastroenterol. 2004 Apr 15;10(8):1132-6. PubMed PMID: 15069712.

201: Ballestrero A, Nencioni A, Boy D, Rocco I, Garuti A, Mela GS, Van Parijs L, Brossart P, Wesselborg S, Patrone F. Tumor necrosis factor-related apoptosis-inducing ligand cooperates with anticancer drugs to overcome chemoresistance in antiapoptotic Bcl-2 family members expressing jurkat cells. Clin Cancer Res. 2004 Feb 15;10(4):1463-70. PubMed PMID: 14977850.

202: Cats A. New developments in systemic chemotherapy in advanced colorectal cancer. Scand J Gastroenterol Suppl. 2003;(239):78-86. Review. PubMed PMID: 14743888.

203: Vekris A, Meynard D, Haaz MC, Bayssas M, Bonnet J, Robert J. Molecular determinants of the cytotoxicity of platinum compounds: the contribution of in silico research. Cancer Res. 2004 Jan 1;64(1):356-62. PubMed PMID: 14729645.

204: Fichtner I, Slisow W, Gill J, Becker M, Elbe B, Hillebrand T, Bibby M. Anticancer drug response and expression of molecular markers in early-passage xenotransplanted colon carcinomas. Eur J Cancer. 2004 Jan;40(2):298-307. PubMed PMID: 14728946.

205: Markman M. Toxicities of the platinum antineoplastic agents. Expert Opin Drug Saf. 2003 Nov;2(6):597-607. Review. PubMed PMID: 14585068.

206: Jung Y, Lippard SJ. Multiple states of stalled T7 RNA polymerase at DNA lesions generated by platinum anticancer agents. J Biol Chem. 2003 Dec 26;278(52):52084-92. Epub 2003 Oct 8. PubMed PMID: 14534300.

207: Zeuli M, Nardoni C, Pino MS, Gamucci T, Gabriele A, Ferraresi V, Giannarelli D, Cognetti F. Phase II study of capecitabine and oxaliplatin as first-line treatment in advanced colorectal cancer. Ann Oncol. 2003 Sep;14(9):1378-82. PubMed PMID: 12954576.

208: Faivre S, Chan D, Salinas R, Woynarowska B, Woynarowski JM. DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells. Biochem Pharmacol. 2003 Jul 15;66(2):225-37. PubMed PMID: 12826265.

209: Fedier A, Schlamminger M, Schwarz VA, Haller U, Howell SB, Fink D. Loss of atm sensitises p53-deficient cells to topoisomerase poisons and antimetabolites. Ann Oncol. 2003 Jun;14(6):938-45. PubMed PMID: 12796033.

210: Fedier A, Steiner RA, Schwarz VA, Lenherr L, Haller U, Fink D. The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells. Int J Oncol. 2003 May;22(5):1169-73. PubMed PMID: 12684687.

211: Scheithauer W. Review of gemcitabine in biliary tract carcinoma. Semin Oncol. 2002 Dec;29(6 Suppl 20):40-5. Review. PubMed PMID: 12577232.

212: Boyer MJ, Rivory LP, Clarke SJ. Pemetrexed: single-agent and combination phase I study overview. Semin Oncol. 2002 Dec;29(6 Suppl 18):18-23. Review. PubMed PMID: 12571806.

213: Kurtz JE, Andrès E, Natarajan-Amé S, Noel E, Dufour P. Oral chemotherapy in colorectal cancer treatment: review of the literature. Eur J Intern Med. 2003 Feb;14(1):18-25. PubMed PMID: 12554006.

214: Jerremalm E, Eksborg S, Ehrsson H. Hydrolysis of oxaliplatin-evaluation of the acid dissociation constant for the oxalato monodentate complex. J Pharm Sci. 2003 Feb;92(2):436-8. PubMed PMID: 12532393.

215: Boughattas NA, Ben Attia M, Ixart G, Lemaigre G, Mechkouri M, Reinberg A. Pharmacological blockage of serotonin biosynthesis and circadian changes in oxaliplatin toxicity in rats. Chronobiol Int. 2002 Nov;19(6):1121-36. PubMed PMID: 12511030.

216: Orlandi L, Binda M, Folini M, Bearzatto A, Villa R, Daidone MG, Zaffaroni N. Ribozyme-mediated inhibition of PKCalpha sensitizes androgen-independent human prostate cancer cells to cisplatin-induced apoptosis. Prostate. 2003 Feb 1;54(2):133-43. PubMed PMID: 12497586.

217: Mormont MC, Levi F. Cancer chronotherapy: principles, applications, and perspectives. Cancer. 2003 Jan 1;97(1):155-69. Review. PubMed PMID: 12491517.

218: Raymond E, Faivre S, Chaney S, Woynarowski J, Cvitkovic E. Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther. 2002 Jan;1(3):227-35. Review. PubMed PMID: 12467217.

219: McMullen KP, Blackstock AW. Chemoradiation with novel agents for rectal cancer. Clin Colorectal Cancer. 2002 May;2(1):24-30. Review. PubMed PMID: 12453333.

220: Fedier A, Ruefenacht UB, Schwarz VA, Haller U, Fink D. Increased sensitivity of p53-deficient cells to anticancer agents due to loss of Pms2. Br J Cancer. 2002 Oct 21;87(9):1027-33. PubMed PMID: 12434296; PubMed Central PMCID: PMC2364320.

221: Woynarowska BA, Woynarowski JM. Preferential targeting of apoptosis in tumor versus normal cells. Biochim Biophys Acta. 2002 Jul 18;1587(2-3):309-17. Review. PubMed PMID: 12084473.

222: Tassone P, Tagliaferri P, Galea E, Palmieri C, Bonelli P, Martelli ML, Tuccillo F, Turco MC, Venuta S. Oxaliplatin (L-OHP) treatment of human myeloma cells induces in vitro growth inhibition and apoptotic cell death. Eur J Cancer. 2002 May;38(8):1141-7. PubMed PMID: 12008204.

223: Giacchetti S. Chronotherapy of colorectal cancer. Chronobiol Int. 2002 Jan;19(1):207-19. PubMed PMID: 11962676.

224: Gent P, Massey K. An overview of chemotherapy-induced peripheral sensory neuropathy, focusing on oxaliplatin. Int J Palliat Nurs. 2001 Jul;7(7):354-9. Review. PubMed PMID: 11951404.

225: Alexandre J, Tigaud JM, Gross-Goupil M, Gornet JM, Romain D, Azoulay D, Misset JL, Goldwasser F. Combination of topotecan and oxaliplatin in inoperable hepatocellular cancer patients. Am J Clin Oncol. 2002 Apr;25(2):198-203. PubMed PMID: 11943903.

226: Lévi F. Circadian chronotherapy for human cancers. Lancet Oncol. 2001 May;2(5):307-15. Review. PubMed PMID: 11905786.

227: Sun Y. Clinical trials of new anticancer agents in recent years in China. Gan To Kagaku Ryoho. 2002 Feb;29 Suppl 1:86-7. PubMed PMID: 11890120.

228: Schenk PW, Boersma AW, Brok M, Burger H, Stoter G, Nooter K. Inactivation of the Saccharomyces cerevisiae SKY1 gene induces a specific modification of the yeast anticancer drug sensitivity profile accompanied by a mutator phenotype. Mol Pharmacol. 2002 Mar;61(3):659-66. PubMed PMID: 11854447.

229: Zeuli M, Costanzo ED, Sdrobolini A, Gasperoni S, Paoloni FP, Carpi A, Moscetti L, Cherubini R, Cognetti F; Gruppo Oncologico Italiano per la Ricerca Clinica (GOIRC) and Gruppo Oncologico Laziale (GOL). Capecitabine and oxaliplatin in advanced colorectal cancer: a dose-finding study. Ann Oncol. 2001 Dec;12(12):1737-41. PubMed PMID: 11843252.

230: Seitz JF, Duffaud F, Dahan L, Ries P, Ville E, Laugier R. [Adenocarcinomas of the distal esophagus and gastric cardia: what chemotherapy or chemoradiotherapy for recurrent or metastatic disease?]. Cancer Radiother. 2001 Nov;5 Suppl 1:107s-112s. French. PubMed PMID: 11797269.

231: McGavin JK, Goa KL. Capecitabine: a review of its use in the treatment of advanced or metastatic colorectal cancer. Drugs. 2001;61(15):2309-26. Review. PubMed PMID: 11772141.

232: Nehls O, Porschen R, Gregor M, Klump B. [The role of oxaliplatin in the therapy for advanced colorectal carcinoma]. Z Gastroenterol. 2001 Dec;39(12):1033-47. Review. German. PubMed PMID: 11753789.

233: Bécouarn Y, Agostini C, Trufflandier N, Boulanger V. Oxaliplatin: available data in non-colorectal gastrointestinal malignancies. Crit Rev Oncol Hematol. 2001 Dec;40(3):265-72. Review. PubMed PMID: 11738949.

234: Zdraveski ZZ, Mello JA, Farinelli CK, Essigmann JM, Marinus MG. MutS preferentially recognizes cisplatin- over oxaliplatin-modified DNA. J Biol Chem. 2002 Jan 11;277(2):1255-60. Epub 2001 Nov 8. PubMed PMID: 11705991.

235: Spingler B, Whittington DA, Lippard SJ. 2.4 A crystal structure of an oxaliplatin 1,2-d(GpG) intrastrand cross-link in a DNA dodecamer duplex. Inorg Chem. 2001 Oct 22;40(22):5596-602. Erratum in: Inorg Chem. 2003 Jan 27;42(2):650. PubMed PMID: 11599959.

236: Goldwasser F, Misset JL. [Clinical use of oxaliplatin in solid tumors]. Bull Cancer. 2001 Aug;88 Spec No:S40-4. Review. French. PubMed PMID: 11567913.

237: Grivicich I, Mans DR, Peters GJ, Schwartsmann G. Irinotecan and oxaliplatin: an overview of the novel chemotherapeutic options for the treatment of advanced colorectal cancer. Braz J Med Biol Res. 2001 Sep;34(9):1087-103. Review. PubMed PMID: 11514832.

238: Caponigro F, Avallone A, Budillon A, Comella P, Comella G. Raltitrexed/5-fluorouracil-based combination chemotherapy regimens in anticancer therapy. Anticancer Drugs. 2001 Jul;12(6):489-97. Review. PubMed PMID: 11459994.

239: Jansman FG, Sleijfer DT, de Graaf JC, Coenen JL, Brouwers JR. Management of chemotherapy-induced adverse effects in the treatment of colorectal cancer. Drug Saf. 2001;24(5):353-67. Review. PubMed PMID: 11419562.

240: Grolleau F, Gamelin L, Boisdron-Celle M, Lapied B, Pelhate M, Gamelin E. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J Neurophysiol. 2001 May;85(5):2293-7. PubMed PMID: 11353042.

241: Mross K, Semsek D. [Chemotherapy of colonic carcinoma in the year 2001]. Praxis (Bern 1994). 2001 Mar 22;90(12):497-510. Review. German. PubMed PMID: 11324309.

242: Berlin J. New directions in the treatment of advanced colorectal cancer. Oncology (Williston Park). 2001 Mar;15(3 Suppl 5):27-30. Review. PubMed PMID: 11301837.

243: Scheithauer W, Kornek GV, Ulrich-Pur H, Penz M, Raderer M, Salek T, Haider K, Kwasny W, Depisch D. Oxaliplatin plus raltitrexed in patients with advanced colorectal carcinoma: results of a Phase I-II trial. Cancer. 2001 Apr 1;91(7):1264-71. PubMed PMID: 11283925.

244: Vaisman A, Warren MW, Chaney SG. The effect of DNA structure on the catalytic efficiency and fidelity of human DNA polymerase beta on templates with platinum-DNA adducts. J Biol Chem. 2001 Jun 1;276(22):18999-9005. Epub 2001 Mar 20. PubMed PMID: 11259423.

245: Jansman FG, Sleijfer DT, Coenen JL, De Graaf JC, Brouwers JR. Risk factors determining chemotherapeutic toxicity in patients with advanced colorectal cancer. Drug Saf. 2000 Oct;23(4):255-78. Review. PubMed PMID: 11051215.

246: Trimble EL. Innovative therapies for advanced ovarian cancer. Semin Oncol. 2000 Jun;27(3 Suppl 7):24-30. Review. PubMed PMID: 10952123.

247: Misset JL, Bleiberg H, Sutherland W, Bekradda M, Cvitkovic E. Oxaliplatin clinical activity: a review. Crit Rev Oncol Hematol. 2000 Aug;35(2):75-93. Review. PubMed PMID: 10936465.

248: O'Dwyer PJ, Stevenson JP, Johnson SW. Clinical pharmacokinetics and administration of established platinum drugs. Drugs. 2000;59 Suppl 4:19-27. Review. PubMed PMID: 10864227.

249: Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S, Bianco AR, Tortora G. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res. 2000 May;6(5):2053-63. PubMed PMID: 10815932.

250: Vaisman A, Masutani C, Hanaoka F, Chaney SG. Efficient translesion replication past oxaliplatin and cisplatin GpG adducts by human DNA polymerase eta. Biochemistry. 2000 Apr 25;39(16):4575-80. PubMed PMID: 10769112.

251: Armand JP, Seymour L, Evans TR. Raltitrexed (Tomudex) in combination with platinum-based agents and/or anthracyclines: preliminary results of phase I clinical trials. Eur J Cancer. 1999 Mar;35 Suppl 1:S14-8. PubMed PMID: 10645209.

252: Kelland LR. Meeting report on 8th International Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy. J Inorg Biochem. 1999 Oct;77(1-2):121-4. PubMed PMID: 10626364.

253: Cvitkovic E, Bekradda M. Oxaliplatin: a new therapeutic option in colorectal cancer. Semin Oncol. 1999 Dec;26(6):647-62. Review. PubMed PMID: 10606258.

254: Mabro M, Faivre S, Raymond E. A risk-benefit assessment of amifostine in cytoprotection. Drug Saf. 1999 Nov;21(5):367-87. Review. PubMed PMID: 10554052.

255: Desrame J, Broustet H, Darodes de Tailly P, Girard D, Saissy JM. Oxaliplatin-induced haemolytic anaemia. Lancet. 1999 Oct 2;354(9185):1179-80. PubMed PMID: 10513718.

256: Lévi F. Cancer chronotherapy. J Pharm Pharmacol. 1999 Aug;51(8):891-8. Review. PubMed PMID: 10504026.

257: Luo FR, Wyrick SD, Chaney SG. Cytotoxicity, cellular uptake, and cellular biotransformations of oxaliplatin in human colon carcinoma cells. Oncol Res. 1998;10(11-12):595-603. PubMed PMID: 10367941.

258: Luo FR, Wyrick SD, Chaney SG. Comparative neurotoxicity of oxaliplatin, ormaplatin, and their biotransformation products utilizing a rat dorsal root ganglia in vitro explant culture model. Cancer Chemother Pharmacol. 1999;44(1):29-38. PubMed PMID: 10367746.

259: Cottu PH, Extra JM, Lerebours F, Espie M, Marty M. [Clinical activity spectrum of irinotecan]. Bull Cancer. 1998 Dec;Spec No:21-5. Review. French. PubMed PMID: 9932080.

260: Raymond E, Chaney SG, Taamma A, Cvitkovic E. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol. 1998 Oct;9(10):1053-71. Review. PubMed PMID: 9834817.

261: Woynarowski JM, Chapman WG, Napier C, Herzig MC, Juniewicz P. Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA. Mol Pharmacol. 1998 Nov;54(5):770-7. PubMed PMID: 9804612.

262: Gamelin E, Boisdron-Celle M, Lebouil A, Turcant A, Cailleux A, Krikorian A, Brienza S, Cvitkovic E, Larra F, Robert J, Allain P. Determination of unbound platinum after oxaliplatin administration: comparison of currently available methods and influence of various parameters. Anticancer Drugs. 1998 Mar;9(3):223-8. PubMed PMID: 9625432.

263: Ducreux M, Louvet C, Bekradda M, Cvitkovic E. Oxaliplatin for the treatment of advanced colorectal cancer: future directions. Semin Oncol. 1998 Apr;25(2 Suppl 5):47-53. Review. PubMed PMID: 9609108.

264: Becouarn Y, Rougier P. Clinical efficacy of oxaliplatin monotherapy: phase II trials in advanced colorectal cancer. Semin Oncol. 1998 Apr;25(2 Suppl 5):23-31. Review. PubMed PMID: 9609105.

265: Raymond E, Lawrence R, Izbicka E, Faivre S, Von Hoff DD. Activity of oxaliplatin against human tumor colony-forming units. Clin Cancer Res. 1998 Apr;4(4):1021-9. PubMed PMID: 9563898.

266: Eriguchi M, Osada I, Fujii Y, Takeda Y, Yoshizaki I, Akiyama N, Yanagie H, Sekiguchi M, Kizu R, Matsushita H, Mathé G. Pilot study for preoperative administration of l-OHP to patients with advanced scirrhous type gastric cancer. Biomed Pharmacother. 1997;51(5):217-20. PubMed PMID: 9247019.

267: Rixe O, Ortuzar W, Alvarez M, Parker R, Reed E, Paull K, Fojo T. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol. 1996 Dec 24;52(12):1855-65. PubMed PMID: 8951344.

268: Lévi F. [Chronopharmacology and chronotherapy of cancers]. Pathol Biol (Paris). 1996 Sep;44(7):631-44. Review. French. PubMed PMID: 8977920.

269: el-akawi Z, Abu-hadid M, Perez R, Glavy J, Zdanowicz J, Creaven PJ, Pendyala L. Altered glutathione metabolism in oxaliplatin resistant ovarian carcinoma cells. Cancer Lett. 1996 Jul 19;105(1):5-14. PubMed PMID: 8689632.

270: Lévi F. Chronotherapy for gastrointestinal cancers. Curr Opin Oncol. 1996 Jul;8(4):334-41. Review. PubMed PMID: 8869810.

271: Lévi F. [Chrono-chemotherapy and dose intensity]. Bull Cancer. 1995;82 Suppl 1:29s-36s. French. PubMed PMID: 7626851.

272: Lévi F. Chronotherapy of cancer: biological basis and clinical application. Pathol Biol (Paris). 1994 Apr;42(4):338-41. Review. PubMed PMID: 7808787.

273: Kelland LR. New platinum antitumor complexes. Crit Rev Oncol Hematol. 1993 Dec;15(3):191-219. Review. PubMed PMID: 8142057.

274: Suzumori K, Yasui Y, Asai H, Yagami Y. [Comparative studies of antitumor activities of oxalate (1R, 2R-cyclohexanediammine) platinum (II) and cis-dichlorodiammine-platinum (II) using ovarian cancer transplanted into nude mice]. Gan To Kagaku Ryoho. 1986 Feb;13(2):280-5. Japanese. PubMed PMID: 3947107.